ArticleInfection and drug resistance2022
Clinical Analysis and Risk Factors of Bronchiolitis Obliterans After Mycoplasma Pneumoniae Pneumonia.
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Risk factors for complications of Mycoplasma pneumoniae pneumonia in hospitalized children in China: a systematic review and meta-analysis.BMC pediatrics · 2024Pooled it
- Pathogenesis and Risk Factors of Post-Infectious Bronchiolitis Obliterans in Children: A Focus on Adenovirus and Mycoplasma Infections.Pathogens (Basel, Switzerland) · 2026Review
- Post-Infectious Bronchiolitis Obliterans as a Model of Immune-Mediated Airway Fibrosis: A Pediatric Case Report.International journal of molecular sciences · 2026Article
- Analysis of risk factors for the development of bronchiolitis obliterans in children with severeFrontiers in medicine · 2026Article
- A Novel Nomogram Integrating Clinical, Radiological, and Immunological Indicators for Early Prediction of SevereJournal of inflammation research · 2026Article
- A nursing perspective on bronchoscopic intervention strategies for children with macrolide-unresponsiveFrontiers in medicine · 2026Article
- A fever-based therapeutic window for bronchoscopy to prevent bronchiolitis obliterans in children with Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- A causal forest model integrating quantitative CT scores to predict benefit from flexible bronchoscopy in pediatric Mycoplasma pneumoniae pneumonia: a two-center retrospective study.Respiratory research · 2025Article
- Risk factors for bronchiolitis obliterans in children with community-acquired pneumonia and analysis of CT findings and clinical manifestations of pneumonia after the diagnosis of bronchiolitis obliterans.Annals of medicine · 2025Article
- Quantitative analysis of pulmonary vascular alterations in children with refractoryQuantitative imaging in medicine and surgery · 2025Article
- Risk factors for bronchiolitis obliterans development in children after Mycoplasma pneumoniae pneumonia: a retrospective study of 981 patients.Italian journal of pediatrics · 2025Article
- Clinical characteristics ofPediatric investigation · 2025Article
- Postinfectious Bronchiolitis Obliterans in Children.Canadian respiratory journal · 2025Review
- Biomarkers associated with the diagnosis and prognosis ofFrontiers in cellular and infection microbiology · 2025Review
- Co-detection of respiratory pathogens in children withFrontiers in pediatrics · 2025Article
- Mycoplasma Pneumoniae bronchiolitis and hypoxemia: A retrospective cohort study on risk and prognosis.PloS one · 2025Article
- Investigation of T lymphocyte subsets in children with Mycoplasma pneumoniae pneumonia.Immunologic research · 2024Article
- Significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia.BMC pulmonary medicine · 2024Article
- Effectiveness of the six-step approach guided online training program to improve knowledge ofTranslational pediatrics · 2024Article
- Clinical features of Mycoplasma pneumoniae pneumonia in children without fever.BMC pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Severe mycoplasma pneumoniae (MP) pneumonia can cause bronchiolitis obliterans (BO). In order to improve the prognosis of BO, it is necessary to grasp the clinical characteristics and risk factors of BO after severe MP pneumonia and intervene as soon as possible. Patients and Methods: This study retrospectively analyzed the clinical data of 110 patients with severe MP pneumonia, and divided them into BO group (22 cases) and non-BO group (88 cases). The clinical characteristics of BO group were analyzed, and the clinical data of two groups were compared to identify the risk factors of BO. Results: At the time of diagnosis, all BO patients had symptoms of cough and wheezing, and 10 (45.45%) had decreased exercise intolerance. Lung function showed moderate to severe obstructive ventilatory dysfunction, high-resolution computed tomography (HRCT) showed mosaic perfusion patterns. Multivariate binomial regression analysis showed that higher levels of serum lactate dehydrogenase (LDH) and hypoxemia were independent risk factors for BO after severe MP pneumonia. Conclusion: Higher levels of serum LDH and hypoxemia were independent risk factors for BO after severe MP pneumonia. For patients with risk factors, clinicians should regular follow-up for early diagnosis and intervention of BO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.